Nexalin Technology (NXL), announced that its proprietary Gen-2 neurostimulation device has received institutional review board, IRB, approval in Brazil for a new clinical trial evaluating its use in the treatment of anxiety disorders and chronic insomnia. The study will be conducted at the Instituto de Psiquiatria do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, one of Latin America’s most prestigious psychiatric research institutions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Nexalin Technology files $50M common stock offering
- Nexalin completes five phases of virtual clinic, digital research system
- Nexalin Technology expresses ‘strong support’ for Health Tech Investment Act
- Nexalin enrolls first patients, advances toward treatment in UCSD trial
- Nexalin Technology upgraded to Buy from Hold at Maxim